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Introduction
From 2005 to 2011, children with the systemic form of
juvenile idiopathic arthritis (JIA), due to the lack of
efficacy of standard antirheumatic therapy, received TNF
inhibitors, because there were no drugs registered for the
treatment of systemic JIA (IL6, IL1 inhibitors) in Russia.
Objectives
Assessment and comparison of efficacy and safety of
TNF-alpha inhibitors (infliximab and etanercept) in the
treatment of children with the systemic form of JIA.
Methods
32 patients with the systemic form of JIA were enrolled in
the study. 19 patients received infliximaband 13 received
etanercept. All patients had high degree (III) of disease
activity. Average disease duration was 7,2 ± 3,3 years.
Before administration of TNF-alpha inhibitors, all patients
received conventional immunosupressive therapy with 2
or more drugs. In the beginning of the disease, systemic
manifestations, such as fever, hepatomegaly, lymphadeno-
pathy, leukocytosis, were observed in 100% of children,
rash in 53% in both groups, persistent joint syndrome in
the infliximab treatment group was seen in 84% of
patients, in the etanercept group - in 73% of children. At
the moment of prescription of TNF - alpha inhibitors, the
mean number of active joints in the whole group was 20 ±
5, the number of joints with restriction of function - 25 ±
7, ESR - 38 ± 12, C-reactive protein - 6,2 ± 3,4. The drugs
were used in standard doses. For assessment of efficacy of
performed therapy, “pediatric” criteria of the American
College of Rheumatology were used: 30%, 50% and 70%
therapy response, that is ACR pedi-30,-50,-70,-90. The
criteria ACR pedi were assessed 6 and 12 months after the
therapy beginning. Achievement of ACR pedi-30,-50 was
regarded as an insufficient response reaction to the ther-
apy being conducted, ACR pedi-70 and higher - as a good
response reaction (achievement of medicament remission
or low disease activity).
Results
In the infliximab treatment group, the good response
was achieved in 31% of patients by the 12th month of
therapy. In children with domination of visceral mani-
festations in the beginning of the disease, infliximab
therapy was ineffective. In the etanercept group, the
good response was achieved in 55% of patients by the
12th month of therapy. In three patients, earlier received
infliximab therapy without distinct effect, etanercept
treatment appeared to be unsuccessful too. The highest
effectiveness of the drugs was registered in children
without extraarticular manifestations of systemic JIA at
the baseline. Further, all children with insufficient
response to the therapy with TNF-alpha inhibitors were
transferred to tocilizumab.
Conclusion
Therapy with TNF-alpha inhibitors has appeared to be
insufficient in the treatment of the systemic form of JIA.
Administration of TNF-alpha inhibitors is justified in
children without extraarticular manifestations of sys-
temic JIA at the moment of prescription of the drug.
No statistically reliable difference in efficacy has been
revealed between infliximab and etanercept groups (p >
0,05). The safety profile of etanercept is significantly
higher than that one of infliximab (p ≤ 0.05). The
received results reconcile with data earlier published in
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